TD Cowen, Truist raise Humana price targets, maintain Hold
TD Cowen analyst Ryan Langston and Truist Securities analyst David Macdonald maintained Hold ratings on Humana while raising price targets to $350 and $415, respectively.
*this image is generated using AI for illustrative purposes only.
TD Cowen analyst Ryan Langston and Truist Securities analyst David Macdonald have maintained Hold ratings on Humana (NYSE: HUM) while raising their respective price targets. The revised targets reflect updated valuation perspectives on the healthcare company's stock, with TD Cowen increasing its target to $350 from $211 and Truist raising its target to $415 from $320.
Rating and Price Action
The decision to retain Hold ratings suggests that while the stocks' potential upside has been reassessed, the risk-reward profiles remain balanced at current levels. The increases in price targets indicate a shift in the firms' fair value estimates for the company.
Key Details
| Firm | Analyst | Rating | Previous Price Target | New Price Target |
|---|---|---|---|---|
| TD Cowen | Ryan Langston | Hold | $211 | $350 |
| Truist Securities | David Macdonald | Hold | $320 | $415 |
What specific factors drove the significant increase in fair value estimates for Humana?
How might the updated price targets influence investor sentiment toward Humana's stock?
Could the Hold ratings indicate lingering concerns about Humana's operational risks?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
